Margaret Anderson is executive director of FasterCures, a nonprofit think tank, catalyst for action and center of the Milken Institute that works across sectors to improve the medical research enterprise. Anderson defines FasterCuresâ€™ strategic priorities, develops its programmatic portfolio, and manages its operations. Before her appointment, she was FasterCures' chief operating officer for five years. Previously Anderson was deputy director at the Center on AIDS and Community Health at the Academy for Educational Development where she managed programs funded by the Ford Foundation, the Annie E. Casey Foundation and the Centers for Disease Control and Prevention; program director at the Society for Women's Health Research where she focused on gender differences in research; a Health Sciences Analyst at the American Public Health Association where she focused on infectious diseases; and project director and analyst in the Biological Applications Program at the Congressional Office of Technology Assessment. She serves as incoming president of the Alliance for a Stronger FDA, is a board member of the Council for American Medical Innovation and the Coalition for the Advancement of Medical Research, co-chairs the e-health Initiativeâ€™s Council on Data and Research, and is involved in numerous health and science policy coalitions and committees. She received a master's degree in science, technology and public policy from George Washington University's Elliott School of International Affairs.
Misha Angrist is Assistant Professor of the Practice at the Duke University Institute for Genome Sciences & Policy. He holds a PhD degree in Genetics from Case Western Reserve University, an MFA in Writing and Literature from the Bennington Writing Seminars, and was formerly a board-eligible genetic counselor. He has covered the biotechnology industry as market-research analyst and worked as an independent life sciences consultant, writer and editor.
In April 2007 he became the fourth subject in Harvard geneticist George Church's Personal Genome Project and in 2009 had his full genome sequenced at Duke. His book, Here is a Human Being: At the Dawn of Personal Genomics, will be published in the fall by Harper Collins.
Linda Avey is co-founder and CEO of Curious, Inc., a personal data discovery platform. Previously, she co-founded 23andMe, the leading personal genetics company.
Professor Bas Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. He received his M.D. degree (with honour) at Leiden University Medical Centre in 1993. In 1994, he obtained his PhD degree in Leiden, based on a thesis entitled "Postural reflexes in Parkinson's disease". He was trained as a neurologist between 1994 and 2000, also at Leiden University Medical Centre. He received additional training as a movement disorders specialist during fellowships at "The Parkinson's Institute", Sunneyvale, California (with Dr. J.W. Langston), and at the Institute of Neurology, Queen Square, London (with Prof. N.P. Quinn and Prof. J.C. Rothwell). In 2002, he founded and became Medical Director of the Parkinson Centre Nijmegen (ParC), which was recognised from 2005 onwards as centre of excellence for Parkinson's disease. Together with Dr. Marten Munneke, he also developed ParkinsonNet, an innovative healthcare concept that now consists of 64 professional networks for Parkinson patients covering all of the Netherlands (www.parkinsonnet.nl). In September 2008, he was appointed as Professor of Neurology, with movement disorders as special area of interest. He is currently President of the International Society for Gait and Postural Research, and is on the editorial board for several national and international journals. Since 2009, he is member of the European Section Executive Committee of the Movement Disorder Society. In 2009, he also joined the board of ZonMw (The Netherlands Organisation for Health Research and Development). He currently has two main research interests: cerebral compensatory mechanisms, especially in the field of gait & balance; and healthcare innovation, aiming to develop and scientifically evaluate patient-centred collaborative care. For this latter purpose, Prof. Bloem co-founded MijnZorgnet (together with Prof. Jan Kremer), a service provider that delivers web-based communities for both patients and health professionals. Prof. Bloem has published over 300 publications, including more than 230 peer-reviewed international papers.
Philip E. Bourne PhD is a Professor in the Department of Pharmacology and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego, Associate Director of the RCSB Protein Data Bank and an Adjunct Professor at the Sanford Burnham Institute. He is a Past President of the International Society for Computational Biology. He is an elected fellow of the American Association for the Advancement of Science (AAAS), the International Society for Computational Biology (ISCB) and the American Medical Informatics Association (AMIA). He is the co-founder and inaugural and current Editor-in-Chief of the open access journal PLoS Computational Biology and a long standing member of the National Science Foundation, National Institutes of Health and Genome Canada panels responsible for reviewing proposals relating to computational biology.
Hugo Campos is the Founder of the ICD User Group.
Henry Chesbrough is Adjunct Professor and Executive Director at the Center for Open Innovation, Haas School of Business, University of California, Berkeley.
George Church, PhD is Professor of Genetics, Harvard Medical School, Wyss Institute, Director of the Center for Computational Genetics, Director of the NIH Center for Excellence in Genomic Science (on human genome engineering), founder of PGP and guinea PiG#1. He is a member of the NAS and NAE and Franklin Laureate for Achievement in Science.
Geoffrey Clapp is a mentor at Rock Health.
Jonathan Derry is Vice President of Research at Sage Bionetworks.
Dr. Aled Edwards oversees the Structural Genomics Consortium (SGC). Trained as a protein biochemist at McGill University and at Stanford University, his group collaborated to determine the structures of many proteins, protein-protein complexes and protein-DNA complexes, mostly in the areas of transcription and DNA replication, and DNA repair.
Kelly Edwards, Ph.D., is an Associate Professor in the Department of Bioethics & Humanities at the University of Washington School of Medicine and Adjunct Associate Professor in the Department of Environmental and Occupational Health. Her training is in Medical Ethics and Philosophy of Education. She teaches and develops curriculum in ethics and professionalism for medical students, residents, and faculty. Dr. Edwards has also served as a curriculum advisor and project co-director for two HRSA contracts to develop genetics curriculum for primary care physicians. She is involved in a number of collaborations that examine justice concerns in genetics research, ethics of community-based research, and international governance models for biobanks.
Dr. Edwards' research interests include clinical decision making, effective approaches to ethics education, and research ethics. Special interests include cultural differences, communication, feminist and narrative approaches to bioethics, research ethics, and integrating ethics into medicine and science education.
She joined the faculty at the Institute for Public Health Genetics in Spring 2002 and directs the Ethics and Outreach Core for the NIEHS-funded Center for Ecogenetics and Environmental Health.
Dr. Ford-Hutchinson is Senior Vice President, Vaccines Research and Development Merck Research Laboratories. He has a 30 year record of success at Merck & Co., Inc. and was Senior Vice President and Site Head of Merck Frosst Canada during the development of SingulairÂ® for the treatment of adult and pediatric asthma and allergic rhinitis and the discovery of selective COX-2 inhibitors for the treatment of osteoarthritis and pain. Before joining Merck he was a lecturer in the Chemical Pathology Department at Kings College Hospital Medical School in London doing leukotriene and prostaglandin research. Dr. Ford-Hutchinson obtained his Bachelorâ€™s Degree in Biochemistry from the University of Birmingham, a Masters Degree in Molecular Enzymology from the University of Warwick, and a Ph.D. in Biochemistry from the University of London.
President, Co-Founder and Director of Sage Bionetworks. Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Robert C. Gentleman is a Canadian statistician and bioinformatician currently working for Genentech. He is recognized, along with Ross Ihaka, as one of the originators of the R programming language and associated software packages like Bioconductor. He got his Ph.D. degree in Statistics from University of Washington in 1988
Kathy Giusti is the Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). In 1998, following her diagnosis with multiple myeloma, Giusti founded the MMRF to fund innovative myeloma research and drug discovery. Having raised more than $120 million to date, the MMRF is the world's number one funder of myeloma research. As an extension of the MMRF's mission, Giusti founded the MMRC in 2004 to enable leading research institutions to work with industry to speed the discovery and development of effective new treatments. Comprising 15 academic institutions across North America, the MMRC is widely recognized for breaking down barriers in tissue banking, data management, genomics, and clinical trials, and is considered an optimal research model to accelerate the development of new therapies. To date, the MMRC has advanced 19 clinical trials of novel compounds and combination approaches through its clinical trials network.
Francois Grey is Professor of Distributed Scientific Computing at the Center for Nano and Micro Mechanics.
Francois Grey has helped to establish the new field of citizen cyberscience in China, through the CNMM project Computing for Clean Water in collaboration with IBMâ€™s World Community Grid. Citizen cyberscience involves adapting scientific challenges so that non-expert volunteers can contribute computing power and brain power to solving them in a fast, low-cost and reliable way. Francoisâ€™ current interests include applications of citizen cyberscience to nanotechnology and biotechnology and geotagging.
Prior to joining CNMM in July 2010, Francois was a Visiting Professor and Senior International Expert with the Chinese Academy of Sciences (CAS), helping to establish the CAS@home volunteer computing project at the Institute of High Energy Physics of CAS in Beijing. He is currently a fellow of the Shuttleworth Foundation for his work in promoting citizen cyberscience in the developing world, and is coordinator of the Citizen Cyberscience Centre, a partnership between CERN, the UN Institute for Training and Research and the University of Geneva.
Eva Guinan received her MD from Harvard Medical School. She completed an internship and residency at Children's Hospital Boston and a fellowship at Children's Hospital/Dana Farber Cancer Institute.
Dr. Guinan received the Clare and Richard Morse Research Award, 2000 the Clinical Translational Scientist Award, Burroughs Wellcome, 1999 and the Distinguished Service Award of the Fanconi Anemia Research Foundation in 2009.
Justin Guinney is a research scientist at Sage Bionetworks.
Magali Haas earned her Bachelor of Science in bioengineering from the University of Pennsylvania, a Master of Science in biomedical engineering degree from Rutgers University, New Jersey, and her medical degree and doctorate in neuroscience from Albert Einstein College of Medicine, New York, under the National Institutes of Health Medical Scientist Training Program. She received the Julius Marmur Research Award from Albert Einstein College of Medicine, in 1997. Dr. Haas joined the Johnson & Johnson organization in 2001 and has gained extensive end-to-end development experience across the various leadership roles she has assumed in medical marketing, full clinical development, early development, translational and biomarker sciences in Psychiatry and Neurology. She oversaw the filing and approval of an antipsychotic for pediatric indications in autism, schizophrenia, and bipolar disorder as well as the clinical Phase 2/3 programs for a novel anticonvulsant drug in epilepsy, migraine and neuropathic pain. She has published over 20 peer-reviewed articles, holds several patents and authored a recent Chapter on Pediatric Trial Methodology. She currently Heads the Department of Integrative Solutions which develops Stratified Medicine strategies and Companion Diagnostics & Solutions for AD, Mood, Schizophrenia and Pain.
David Haussler is the Distinguished Professor of Biomolecular Engineering and Director of the Center for Biomolecular Science & Engineering at the University of California, Santa Cruz.
David Haussler's research lies at the interface of mathematics, computer science, and molecular biology. He develops new statistical and algorithmic methods to explore the molecular function and evolution of the human genome, integrating cross-species comparative and high-throughput genomics data to study gene structure, function, and regulation. He is credited with pioneering the use of hidden Markov models (HMMs), stochastic context-free grammars, and the discriminative kernel method for analyzing DNA, RNA, and protein sequences. He was the first to apply the latter methods to the genome-wide search for gene expression biomarkers in cancer, now a major effort of his laboratory.
Joseph Hellerstein is the Manager of Computational Discovery for Science (eScience) at Google.
James Heywood is the Co-Founder and Chairman of Patients Like Me.
Dr. Hill currently serves as the Executive Director of the International Neuroinformatics Coordinating Facility, and has previously served as the Project Manager for Computational Neuroscience in the Blue Brain Project at the EPFL and with IBM Research. He has also supervised and led research efforts exploring the principles underlying the structure and dynamics of neocortical microcircuitry. Dr. Hill holds a Bachelor of Arts degree in Computational Neuroscience from Hampshire College (Amherst, MA), and a PhD in Computational Neuroscience from the University of Lausanne (Switzerland). His PhD research focused on an investigation of the computational role of the auditory thalamocortical circuitry in the rat, which involved multi-unit recordings and large-scale neuronal simulations. After receiving his PhD, Dr. Hill held postdoctoral positions at The Neurosciences Institute of La Jolla, CA and the University of Wisconsin, Madison. His research interests include the use of biologically-realistic models to study the role of emergent phenomena in information processing, network connectivity and synaptic plasticity in the central nervous system, from the neocortical column to the whole brain, and across different arousal conditions including waking and sleep.
Professor Lawrence Hunter is Director of the Center for Computational Biology and of the Computational Bioscience Program at the University of Colorado School of Medicine. He is an internationally known scholar, focused on computational biology, knowledge-driven extraction of information from the primary biomedical literature, the semantic integration of knowledge resources in molecular biology, and the use of knowledge in the analysis of high-throughput data, as well as for his foundational work in computational biology, which led to the genesis of the major professional organization in the field and two international conferences.
Thomas R. Insel, M.D., is Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating the knowledge needed to understand, treat, and prevent mental disorders. His tenure at NIMH has been distinguished by groundbreaking findings in the areas of practical clinical trials, autism research, and the role of genetics in mental illnesses.
Prior to his appointment as NIMH Director in the Fall 2002, Dr. Insel was Professor of Psychiatry at Emory University. There, he was founding director of the Center for Behavioral Neuroscience, one of the largest science and technology centers funded by the National Science Foundation and, concurrently, director of an NIH-funded Center for Autism Research. From 1994 to 1999, he was Director of the Yerkes Regional Primate Research Center in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at NIMH studying the neurobiology of complex social behaviors. He has published over 250 scientific articles and four books, including the Neurobiology of Parental Care (with Michael Numan) in 2003.
Dr. Insel has served on numerous academic, scientific, and professional committees and boards. He is a member of the Institute of Medicine, a fellow of the American College of Neuropsychopharmacology, and is a recipient of several awards including the Outstanding Service Award from the U.S. Public Health Service. Dr. Insel graduated from the combined B.A.-M.D. program at Boston University in 1974. He did his internship at Berkshire Medical Center, Pittsfield, Massachusetts, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.
Tyler Jenks has spent his entire professional career studying financial markets and investments. Mr. Jenks is currently President and Chief Investment Officer of Lucid Investment Strategies, a division of Dumont and Blake. Mr. Jenks has served the last ten years as President and Chief Investment Officer of Amivest Capital Management/NFB Asset Builder, North Fork Bank's investment advisory division. Mr. Jenks served as Senior Portfolio Manager upon joining Amivest Capital Management in 1991, and was named Amivest's Chief Investment Officer in 1998 when North Fork Bank acquired the firm. After graduating with a degree in International Relations from Principia College in 1971, Mr. Jenks spent four years as an officer in the United States Coast Guard. While stationed in Hawaii, Mr. Jenks received his M.B.A. from the University of Hawaii. Immediately following his military service, Mr. Jenks joined a major Wall Street firm and has spent the last 31 years as a student of markets and investments. During his career, Tyler has had the opportunity to work with some of the most accomplished chief investment officers, portfolio managers, fundamental and technical analysts, market timers, theoreticians and academicians in the business.
Jason Johnson is the Executive Director of the Informatics IT Department at Merck.
Heather Joseph has served as the Executive Director of the Scholarly Publishing and Academic Resources Coalition (SPARC) since 2005. In that capacity, she works to support broadening access to the results of scholarly research through enabling open access publishing, archiving and policies on a local, national and international level.
Ms. Joseph is also the convener of the Alliance for Taxpayer Access, a coalition of universities, libraries, patients advocacy groups, consumer groups, and student organizations who work to ensure that results of publicly funded research are openly accessible to the public. The group has been a leading voice on U.S. open access legislation, including landmark policy issued by the National Institutes of Health (NIH).
Prior to coming to SPARC, she spent 15 years as a publisher in both commercial and not-for-profit publishing organizations. She served as the publishing director at the American Society for Cell Biology, which became the first journal to commit its full content to the NIHâ€™s pioneering open repository, PubMed Central, and subsequently served on the National Advisory Committee for the project.
Ms. Joseph serves on the Board of Directors of numerous not-for-profit organizations, and recently completed a term as the elected President of the Society for Scholarly Publishing. She is a frequent speaker and writer on scholarly communications in general, and on open access in particular.
Peter Kapitein is President and patient advocate of inspire2live.
Jane Kaye is Director of the Centre for Law, Health and Emerging Technologies at Oxford: (HeLEX) based in the Department of Public Health at the University of Oxford. She obtained her degrees from the Australian National University (BA); University of Melbourne (LLB); and University of Oxford (DPhil). She was admitted to practice as a solicitor/barrister in 1997. She is advisor to a number of F7 projects and on the Sample and Ethics Committee of the 1000 Genomes Project; International Scientific Advisory Board Canadians for Tomorrow Project; UK10K Ethics Advisory Group and Chair of the CARTaGENE International Scientific Advisory Board, Canada. She is also on the editorial boards of Law, Innovation and Technology, Journal of Law and Information Science, and Genomics, Policy and Society.
Her research involves investigating the relationships between law, ethics, and practice in the area of emerging technologies in health. The main focus is on genomics with an emphasis on biobanks, privacy, data-sharing frameworks, global governance and translational research
Michael M. Kellen currently serves as vice chairman of Arnhold and S. Bleichroeder Advisers, LLC and as co-president and co-chief executive officer of Arnhold and S. Bleichroeder Holdings, Inc. Kellen is on the Board of Trustees at the Cancer Research Institute.
Dr. Regis B. Kelly is the Director of one of four California Institutes for Science and Innovation, created by the California Legislature to strengthen the academic foundation of its technology-based industries. QB3 is the only one of the four devoted exclusively to biology and to the life science industries. It is an innovation center made up of over 200 quantitative biologists at three northern California campuses (UCB, UCSC & UCSF) working at the interface of the physical and biological sciences and a team of professionals converting its discoveries into practical benefits for society.
Iya Khalil oversees the application of the companyâ€™s simulation technology to critical challenges in the healthcare industry.
A frequent speaker at industry events and conferences, she has extensive experience in reverse engineering and forward simulations of large-scale genetic and biochemical networks. Iya is an inventor on a number of pending patents and has published multiple articles on in silico technologies applied to drug discovery and development. Prior to joining GNS Healthcare, she worked at Cornell University, University of Washington, and Abbott Labs. Iya holds a B.S. in physics from the University of Washington and a Ph.D. in physics from Cornell University.
Richard D. Klausner is Managing Partner of The Column Group, a venture capital fund focused on building the next generation of drug discovery and development companies. Dr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. Prior to that he served as Director of the National Cancer Institute from 1995 to 2001.
Dr. Klausner's research in hematology has been recognized with many awards, including the William Damashek Prize and the Outstanding Investigator Award of the American Federation of Clinical Research. He has served as an adviser to the Presidents of the National Academies for counter-terrorism and as a liaison to the White House Office of Science and Technology Policy. Dr. Klausner is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Chitra is Changemakers' Director of Knowledge and Learning. Prior to joining Ashoka, she worked for 7 years in the Department of Neurology at Johns Hopkins University where she helped develop a clinical center of excellence in a rare disease of the nervous system and conducted clinical translational research. She also co-founded an initiative called Project RESTORE at Hopkins, to expand institutional research and patient care out into the community and be a vehicle of change to transform the way diseases are traditionally studied. She holds a Masters in Health Systems Management from the Johns Hopkins Bloomberg School of Public Health.
Vessela N. Kristensen works in the Department of Genetics at the Institute of Cancer Research, Norwegian Radium Hospital.
Mr. Kupershmidt leads NextBio's product, scientific computing and content groups. His team includes PhDs and MDs from leading academic institutions with extensive experience in genomics, computational biology and clinical research. Mr. Kupershmidt has a decade of experience in the design and implementation of genomic solutions for organizations involved in basic and translational research, as well as drug discovery.
Prior to NextBio, Mr. Kupershmidt was the Director of Professional Services at Silicon Genetics. There he helped develop and customize software solutions for the analysis and management of high throughput data generated by genomic and proteomic technologies. Mr. Kupershmidt joined Silicon Genetics as an early stage startup and successfully worked with hundreds of academic institutions and commercial enterprises.
Previously, Mr. Kupershmidt carried out research as a geneticist at the UCSD Howard Hughes Medical Institute where he studied transcriptional mechanisms of gene expression regulation during pituitary development. Mr. Kupershmidt is currently a PhD candidate at the SciLifeLab Institute, in Stockholm, Sweden.
Lawrence Lessig is one of our most respected voices on the legal, political, and cultural implications of digital technology. Currently the Roy L. Furman Professor of Law and Leadership at Harvard Law School, Lessig founded Creative Commons in 2001 to reboot our antiquated copyright system. He is also the director of Harvard’s Edmond J. Safra Center for Ethics and the founder of Rootstrikers, an activist network working to reduce the influence of money in politics. In 2000, as a professor at Stanford, he founded the school’s Center for Internet and Society. Lessig is the author of numerous books, including Code: And Other Laws of Cyberspace; The Future of Ideas: The Fate of the Commons in a Connected World; Remix: Making Art and Commerce Thrive in the Hybrid Economy; and Republic, Lost: How Money Corrupts Congress—and a Plan to Stop It. A member of the American Academy of Arts and Sciences and the American Philosophical Association, he has received numerous honors and was named one of the world’s “Top 50 Visionaries” by Scientific American.
Susan Love: Physician and cofounder of the National Breast Cancer Coalition and the Dr. Susan Love Research Foundation.
Lara Mangravite is Sr. Scientist of Systems Biology at Sage Bionetworks.
Adam Margolin is the lead of Sage Bionetworks' Academic Institutional Reward Board.
Beverly Mayhew is the Executive Director of Fanconi Anemia Research.
Barbara B. Mittleman, M.D. is the Director of NIH's (National Institutes of Health) Public-Private Partnership Program. In that capacity, she oversees activities to develop and implement policy, to facilitate access of NIH and a wide range of outside partners from industry, public advocacy, professional societies and government agencies to one another, and promotes the partnership from inception to launch to manifestation. She was instrumental in the negotiations that led to the formation of The Biomarkers Consortium, co-chaired the first mHealth Summit in 2009, and works closely with NIH Institutes and Centers to enhance partnership opportunities and success. Her training is in internal medicine and rheumatology, encompassing both clinical and basic science aspects of autoimmunity. She graduated from the University of Pittsburgh Medical School and completed residency and fellowship training there. She came to NIH in 1991 to pursue post-doctoral training in cellular immunology, eventually heading up a laboratory in the National Institute of Mental Health focusing on the immunology of psychiatric disease. She then moved to the National Institute of Arthritis and Musculoskeletal and Skin Diseases as the Director of Scientific Interchange, where she facilitated partnerships, one of which involved the founding of a community research clinic and partnerships with some 60 plus community organization. She came to the NIH Office of the Director, Office of Science Policy in 2005, at the inauguration of the Program on Public-Private Partnerships as the founding director. Her publications include work in the cellular immune aspects of autoimmune and psychiatric disease, health disparities, and partnerships.
Thea Norman is Director of Strategic Development at Sage Bionetworks.
John Quackenbush is an American computational biologist and genome scientist. He is the Professor of Biostatistics and Computational Biology, Professor of Cancer Biology at the Dana-Farber Cancer Institute (DFCI), as well as the director of its Center for Cancer Computational Biology (CCCB). Quackenbush also holds an appointment as Professor of Computational Biology and Bioinformatics in the Department of Biostatistics at the Harvard School of Public Health (HSPH).
Krishanu Saha is an STS and Society in Science Branco-Weiss Fellow. Kris seeks to expand his background in working with nascent human engineered materials to investigate the modeling of diseases at the cellular level with human â€œreprogrammedâ€ stem cell lines. By drawing on analytical tools in both science and STS, this project will examine the assumptions built into â€œdiseases in a dish.â€ As these diseases in a dish are constructed through stem cell biology and engineering, laboratory work will be extended to examine the moral, economic, and political status of these objects.
Kris studied Chemical Engineering at Cornell University and University of California, Berkeley. In his dissertation he worked on experimental and computational analyses of neural stem cell development, as well as the design of new materials for adult stem cell culture.
In 2007 he moved to the laboratory of Rudolf Jaenisch at the Whitehead Institute for Biomedical Research at MIT in Cambridge, Massachusetts as a postdoctoral fellow. Since 2006 he has worked with human embryonic stem cells and the institutional policies surrounding them.
Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences, the next-generation sequencing technology provider. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).
John Schrom is a fellow at Rock Health.
Vicki L. Seyfert-Margolis
Vicki Seyfert-Margolis, Ph.D., serves as the Senior Science Advisor to the FDA's Chief Scientist in the mission of upgrading science, with a focus on bioinformatics and advancing regulatory science. She has most recently been Chief Scientific Officer at Immune Tolerance Network, a non-profit consortium of researchers seeking new treatments for diseases of the immune system; and an Adjunct Associate Professor with the Department of Medicine at the University of California - San Francisco.
Prior to that, Seyfert-Margolis was a program director in innovative scientific research at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Seyfert-Margolis research interests are: Immunology, biomarker development, advancing scientific computing environment/high density data, health information technology, validation and standards development.
Michael Simpson is CEO of Traitwise.
Ron Snelders is the Project Manager of the Discovery Network project.
Dr. Stephan is a human geneticist who works to understand the root causes of common human diseases so that early diagnostics and interventions can be implemented. Dr. Stephan most recently was the deputy director of discovery research at the Translational Genomics Research Institute and still holds a faculty appointment there. Dr. Stephan has identified genes that predispose to disorders such as autism, exercise-induced heart attacks and sudden infant death syndrome, and contributed to understanding a multitude of common "complex genetic" disorders such as Alzheimer's disease.
Dr. Stephan is chairman of the National Institutes of Health (NIH) Neuroscience Microarray Consortium, and has previously held faculty appointments at Johns Hopkins University, the National Human Genome Research Institute of the NIH, the University of Arizona, Arizona State University, George Washington University and the Children's National Medical Center in Washington, D.C. Dr. Stephan has published extensively in journals such as Science, the Proceedings of the National Academy of Sciences, Nature Genetics and the New England Journal of Medicine. Dr. Stephan received his B.S. at Carnegie-Mellon University and his Ph.D. at the University of Pittsburgh, and trained as a fellow at the National Human Genome Research Institute of the NIH.
Over the last eight years, François Taddei has created the CRI (Center for Research and Interdisciplinary) in Paris. CRI’s main role is to promote new pedagogies to help creative students take initiatives and develop their research projects, with the help of mentors, research institutions, private companies, and foundations, such as the Bettencourt Foundation, which has supported many student-created activities. These activities range from the first French synthetic biology team (for the MIT-sponsored iGEM competition) to the Paris-Montagne science festival and the Science Académie, an outreach program that allows high schools students from deprived neighbourhoods to discover the creativity of science. The CRI offers three programs integrated in the Liliane Bettencourt curriculum: a new undergrad program, a Master’s degree (Innovative Approaches to Research and Education, IARE), and a doctoral school (Frontiers of Life, FdV). CRI‘s dedicated facilities host visiting professors, a wide choice of courses and several student discussion clubs.
François Taddei has taken the lead of the new Institute for Learning Through Research that has been selected in March 2012 by the International Scientific Committee of the National Innovative Training Program (IDEFI) of the French ministry of research.
François Taddei also heads the Evolutionary Systems Biology team at a unit of the French National Institute of Health & Medical Research (INSERM) in Paris-Descartes University’s Medical School. His work has produced many publications in general-interest scientific journals, and has been recognized by several international and national awards. François Taddei participates in various working groups on the future of research and education (France 2025, OECD, EU, etc.).
Dr. Marty Tenenbaum
Marty Tenenbaum is the Chairman of CollabRx, a provider of Web-based applications and services that help cancer patients and their physicians selectoptimal treatments and trials. Dr. Tenenbaum is also the founder of CancerCommons, an open science community that compiles and continually refinesinformation about cancer subtypes and treatments, based on the literature andactual patient outcomes.
Dr. Tenenbaum was educated at MIT and Stanford in the 1960s. He spent the 1970s doing artificial intelligence research at SRI, the 1980s managing computer science research for Schlumberger, and the 1990s pioneering Internet commerce. He is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Patients Like Me, the Public Library of Science, Efficient Finance, and Earth Analytics Group.
Sharon F. Terry is President and CEO of Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. Genetic Alliance enables individuals, families and communities to reclaim their health and become full participants in translational research. She is the founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). As co-discoverer of the gene associated with PXE, she holds the patent for ABCC6 to act as its steward and has assigned her rights to the foundation. She developed a diagnostic test and conducts clinical trials. Terry is also a co-founder of the Genetic Alliance Registry and Biobank. She is the author of more than 100 peer-reviewed articles. In her focus at the forefront of consumer participation in genetics research, services and policy, she serves in a leadership role on many of the major international and national organizations.
Adrien Treuille is Assistant Professor of the Computer Graphics group at Carnegie Mellon's Robotics Institute. He was one of the creators of Foldit, the computer game where users contribute to science by folding proteins. He also studies the simulation and animation of very high-dimensional nonlinear phenomena like animal morphology, human motion, and large fluid systems. One thread of Dr. Treuille's research addresses the complexity of such systems by developing model reduction tools that generate compact representations. A complementary thread seeks to control such systems, which means learning to set inputs to produce desired effects. While Dr. Treuille seeks theoretical advances, he is also deeply interested in the implications for science and engineering of these techniques, from fluid dynamics to laying down a joint cognitive and biomechanical basis for animal motion. His interests also extend to computer graphics, numerical computation, model reduction, and scientific discovery games.
Laura Van't Veer
Dr. van't Veer is a world renowned Molecular Pathologist, former Head of Diagnostic Oncology at the Netherlands Cancer Institute, and inventor of MammaPrintïƒ’. She is the P.I. of the Bay Area Breast SPORE and Leader of the Breast Oncology Program in the Helen Diller Family Comprehensive Cancer Center. Dr. van't Veer's research focuses on Personalized Medicine, to advance that patient management is based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows to optimally assign systemic therapy for those patients that are in need of such treatment and to ensure the selection of the therapy that is most effective. Dr. van't Veer's research shows that molecular diagnostics and microarray genomics technology increasingly impacts patient management. Molecular Genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy.
Vriesendorp is a radiation oncologist from Syracuse, NY, USA. He was employed by the Erasmus University Medical Center in Rotterdam, the Radiobiological Institute of TNO in Rijswijk (The Netherlands)
Dr. Markus Warmuth joined H3 Biomedicine as Chief Scientific Officer in August 2011 and became President and Chief Executive Officer on October 1, 2011. Markus brings significant experience in cancer biology, drug discovery and clinical oncology to H3. During his career as a pharmaceutical industry research executive, he has successfully built and shaped oncology research groups and portfolios.
Prior to joining H3, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site. There, he oversaw a significant part of NIBRâ€™s global oncology drug discovery portfolio from target discovery to clinical development.
Markus studied and received his doctorate in Medicine from the Ludwig-Maximilians-University of Munich, Germany. He trained in Internal Medicine and Oncology at the University of Munich. From 1998 to 2002, he had an appointment as a principal scientist with the â€œClinical Cooperation Group Signalingâ€ at the German National Research Center of Environment and Health (GSF), where he studied the mechanism of action of and resistance to multiple small molecule kinase inhibitors in leukemia and lymphoma.
As VP of Science, John Wilbanks runs the Science Commons project at Creative Commons. He came to Creative Commons from a Fellowship at the World Wide Web Consortium in Semantic Web for Life Sciences. Previously, he founded and led to acquisition Incellico, a bioinformatics company that built semantic graph networks for use in pharmaceutical research & development. Previously, John was the first Assistant Director at the Berkman Center for Internet and Society at Harvard Law School and also worked in US politics as a legislative aide to U.S. Representative Fortney (Pete) Stark.
John holds a Bachelor of Arts in Philosophy from Tulane University and studied modern letters at the Universite de Paris IV (La Sorbonne). He was a research affiliate at the MIT Computer Science and Artificial Intelligence Laboratory in the project on Mathematics and Computation. John also serves on the Advisory Boards of the U.S. National Library of Medicine’s PubMed Central, the Open Knowledge Foundation, the Open Knowledge Definition, and the International Advisory Board of the Prix Ars Electronica’s Digital Communities awards. He also serves on the Board of Directors of the Fedora Commons digital repository organization.
About this conference
2012 will be the third Commons Congress. Sage Bionetworks is in its fourth year and is deep into the transition from non-profit start-up to a provider of fundamental new infrastructure for network biology. The first part of the Congress will focus on this transition and the progress to date on how early investments in technical and legal data sharing platforms are beginning to pay off in faster science, increased patient engagement, and disruptive projects that can shake up the entire pharmaceutical industry. The second part will review activities and opportunities in ongoing pilots and projects. The third part will highlight emerging projects designed to shift sharing behaviors in drug development (Arch2POCM) and in disrupting the current medical-industrial social value chain. The concluding part four will be a community effort to look at what is required to move beyond the current medical information system and its rewards.
About Sage Bionetworks
Sage Bionetworks was formed as a strategic nonprofit research organization with a mission to coordinate and link academic and commercial biomedical researchers through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation, and contributor-evolved resources.
We are located on the campus of the Fred Hutchinson Cancer Research Center in Seattle, Washington and are supported through a portfolio of philanthropic donations, competitive research grants, and commercial partnerships.